Dr. Gay Discusses the Efficacy Data from the FORTE Trial in Myeloma

Francesca Gay, MD, PhD
Published: Thursday, Jun 28, 2018



Francesca Gay, MD, PhD, hematologist, Myeloma Unit, Division of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, discusses the updated efficacy data from the FORTE trial of patients with newly-diagnosed multiple myeloma.

In the study of 474 patients, 315 were treated with carfilzomib (Kyprolis), lenalidomide (Revlimid) and dexamethasone (KRd), and 159 were treated with carfilzomib, cyclophosphamide and dexamethasone (KCd). The rate of partial response (PR) after induction was very high in both arms, Gay says, with a 97% PR in patients treated with KRd, and a 91% PR in patients treated with KCd. However, the depth of response was higher in patients treated with KRd who received a very good PR or a stringent complete response.

A subset of patients were also evaluated for minimum residual disease (MRD) negativity. The rate of MRD negativity for patients treated with KRd was 56%, and for patients treated with KCd, MRD negativity was 29% (P = 0.008). Additionally, treatment in both arms was well tolerated.


Francesca Gay, MD, PhD, hematologist, Myeloma Unit, Division of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza, discusses the updated efficacy data from the FORTE trial of patients with newly-diagnosed multiple myeloma.

In the study of 474 patients, 315 were treated with carfilzomib (Kyprolis), lenalidomide (Revlimid) and dexamethasone (KRd), and 159 were treated with carfilzomib, cyclophosphamide and dexamethasone (KCd). The rate of partial response (PR) after induction was very high in both arms, Gay says, with a 97% PR in patients treated with KRd, and a 91% PR in patients treated with KCd. However, the depth of response was higher in patients treated with KRd who received a very good PR or a stringent complete response.

A subset of patients were also evaluated for minimum residual disease (MRD) negativity. The rate of MRD negativity for patients treated with KRd was 56%, and for patients treated with KCd, MRD negativity was 29% (P = 0.008). Additionally, treatment in both arms was well tolerated.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x